Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 20/20 | 0.57 |
| ▸ | JAK3 | P52333 | 19/20 | 0.57 |
| ▸ | JAK1 | P23458 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8223240 | 1.00 | JAK2 (0.57) | JAK2JAK3JAK1 | |
| SCHEMBL8220476 | 1.00 | JAK2 (0.57) | JAK2JAK3JAK1 | |
| SCHEMBL6525499 | 1.00 | JAK2 (0.57) | JAK2JAK3JAK1 | |
| SCHEMBL6525003 | 0.87 | JAK2 (0.55) | JAK2JAK3JAK1 | |
| SCHEMBL8222508 | 0.87 | JAK2 (0.55) | JAK2JAK3JAK1 | |
| SCHEMBL8216745 | 0.84 | JAK2 (0.56) | JAK2JAK3JAK1 | |
| SCHEMBL8216749 | 0.84 | JAK2 (0.56) | JAK2JAK3JAK1 | |
| SCHEMBL8224445 | 0.84 | ALOX5AP (0.43) | JAK2JAK3JAK1 | |
| SCHEMBL8224443 | 0.84 | ALOX5AP (0.43) | JAK2JAK3JAK1 | |
| SCHEMBL8219667 | 0.80 | JAK2 (0.53) | JAK2JAK3JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618103-B2 | Inhibitors of JAK | HOFFMANN-LA ROCHE INC. (US) | 2013-12-31 | — | — | US | claimed |
| US-20110059118-A1 | INHIBITORS OF JAK | DE VICENTE FIDALGO JAVIER | 2011-03-10 | — | — | US | claimed |
| US-8618103-B2 | Inhibitors of JAK | HOFFMANN-LA ROCHE INC. (US) | 2013-12-31 | — | — | US | disclosed |
| EP-2475667-A1 | INHIBITORS OF JAK | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011029804-A1 | INHIBITORS OF JAK | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| US-20110059118-A1 | INHIBITORS OF JAK | DE VICENTE FIDALGO JAVIER | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059118-A1 | INHIBITORS OF JAK | JAK1, JAK3, JAK2 | JAK2 3/4885JAK3 2/4885JAK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.